For the NCOA4-RET fusion-positive, ER+/ERBB2-amplified breast cancer, one can speculate that the presence of NCOA4-RET contributed to its relative resistance to primary treatment with aromatase inhibitor, trastuzumab, and pertuzumab. Here, NCOA4 is linked to breast carcinoma.